Galapagos NV (Galapagos NV) EV-to-EBITDA

: -293.77 (As of Today)

View and export this data going back to 2005. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Galapagos NV's enterprise value is $-1,980.3 Mil. Galapagos NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $6.7 Mil. Therefore, Galapagos NV's EV-to-EBITDA for today is -293.77.

The historical rank and industry rank for Galapagos NV's EV-to-EBITDA or its related term are showing as below:

GLPGF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2830.22 Med: -20.94 Max: 67.61
Current: -251.36

During the past 13 years, the highest EV-to-EBITDA of Galapagos NV was 67.61. The lowest was -2830.22. And the median was -20.94.

GLPGF's EV-to-EBITDA is ranked better than
99.79% of 474 companies
in the Biotechnology industry
Industry Median: 9.165 vs GLPGF: -251.36

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-24), Galapagos NV's stock price is $35.5157. Galapagos NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $3.484. Therefore, Galapagos NV's PE Ratio for today is 10.19.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Galapagos NV EV-to-EBITDA Historical Data

The historical data trend for Galapagos NV's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

Get a 7-Day Free Trial

38.86

-0.47

19.81

-348.62

-24.24

Galapagos NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															-348.62	63.72	-289.70	-317.94	-24.24

Competitive Comparison

For the Biotechnology subindustry, Galapagos NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galapagos NV EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Galapagos NV's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Galapagos NV's EV-to-EBITDA falls into.

Galapagos NV EV-to-EBITDA Calculation

Galapagos NV's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	-1980.271	/	6.741
	=	-293.77

Galapagos NV's current Enterprise Value is $-1,980.3 Mil.
Galapagos NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.7 Mil.

Galapagos NV (OTCPK:GLPGF) EV-to-EBITDA Explanation

Galapagos NV's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	35.5157	/	3.484
	=	10.19

Galapagos NV's share price for today is $35.5157.
Galapagos NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.484.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Galapagos NV EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Galapagos NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV (Galapagos NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (OTCPK:GLPGF) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

GLPG:USA GLPG:Netherlands GLPG:Mexico 0JXZ:UK GXE:Germany GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.